By Doug Macron

Alnylam Pharmaceuticals last week announced that it has advanced its preclinical TTR amyloidosis therapeutic candidate into its formal drug-development pipeline, aiming to file an investigational new drug application on the systemically administered drug by the end of 2009.

The company made the disclosure as part of an announcement of its second-quarter financial results, which included a roughly 77 percent jump in net loss as research and development spending swelled more than 30 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.